Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Blood (2025) 146 (Supplement 1): 669.

https://doi.org/10.1182/blood-2025-669

Published: 2025

Journal Articles

Hypomethylating agents or chemotherapy in combination with venetoclax and gilteritinib for FLT3-mutated Acute Myeloid Leukemia

Andrius Zucenka, Milda Mikalonyte, Tautvile Smalinskaite, Lukas Kevlicius, Guoda Daukelaite, Regina Pileckyte, Linas Davainis, Birute Davainiene, Igoris Trociukas, Rita Cekauskiene, Valdas Peceliunas, Laimonas Griškevičius

Blood (2025) 146 (Supplement 1): 1679.

https://doi.org/10.1182/blood-2025-1679

Published: 2025

Journal Articles

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group

Blood (2025) 146 (Supplement 1): 1676.

https://doi.org/10.1182/blood-2025-1676

Published: 2025

Journal Articles

Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group

Blood (2025) 146 (Supplement 1): 1709.

https://doi.org/10.1182/blood-2025-1709

Published: 2025

Journal Articles

Next-generation sequencing-based mutation profile in secondary compared to de novo acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 6069.

https://doi.org/10.1182/blood-2025-6069

Published: 2025

Journal Articles

Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication

Pierre Bories, Mojca Jongen-Lavrencic, Laimonas Griškevičius, Thomas Pabst, David de Leeuw, Gerwin A. Huls, Nicolas Boissel, Arnaud Pigneux, Steffen Boettcher, Mariola Dymkowska, Christiane Andrieu, Elena Fernandez, Paul Baverel, Vaia Stavropoulou, Michael Sanderson, Vladimir Kirkin, Philippe Legenne, Marion Subklewe

Blood (2025) 146 (Supplement 1): 3419.

https://doi.org/10.1182/blood-2025-3419

Published: 2025

Journal Articles

Conditioning with alkylating agents, cytarabine, cladribine, hypomethylating agents, and venetoclax (ARCHIVE) for upfront allogeneic stem cell transplantation in patients with active Acute Myeloid Leukemia or myelodysplastic syndrome with increased blasts-2

Andrius Zucenka, Lukas Kevlicius, Tautvile Smalinskaite, Guoda Daukelaite, Milda Mikalonyte, Igoris Trociukas, Linas Davainis, Arturas Slobinas, Rita Cekauskiene, Renata Jucaitiene, Inga Slepikiene, Adomas Bukauskas, Vaida Jaramine, Juste Strumskyte, Antanas Griskevicius, Arturas Jakubauskas, Valdas Peceliunas, Laimonas Griškevičius

Blood (2025) 146 (Supplement 1): 2415.

https://doi.org/10.1182/blood-2025-2415

Published: 2025

Journal Articles

Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 464.

https://doi.org/10.1182/blood-2024-202279

Published: 2024

Journal Articles

Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT

Blood (2024) 144 (Supplement 1): 2188.

https://doi.org/10.1182/blood-2024-200501

Published: 2024

Journal Articles

No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 693.

https://doi.org/10.1182/blood-2024-203472

Published: 2024

Journal Articles

The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Laura G.M. Daenen, Lotte Van Der Wagen, Edouard F. Bonneville, Lucia Lopez Corral, Laimonas Griskevicius, Martin Bornhäuser, Yves Beguin, Maija Itala-Remes, Jorinde D. Hoogenboom, Liesbeth C. de Wreede, Florent Malard, Christian Chabannon, Francesco Dazzi, Annalisa Ruggeri, Jurgen Kuball

Blood (2024) 144 (Supplement 1): 4907.

https://doi.org/10.1182/blood-2024-201358

Published: 2024

Journal Articles

Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 4942.

https://doi.org/10.1182/blood-2024-204672

Published: 2024

Journal Articles

Frontline Sequential Allogeneic Stem Cell Transplantation for Newly Diagnosed Acute Myeloid Leukemia with 3q26.2/ Mecom Rearrangement

Andrius Žučenka, Lukas Kevličius, Linas Davainis, Igoris Trociukas, Rita Čekauskienė, Vaida Jaraminė, Justė Strumskytė, Raminta Batiuškaitė, Rimvydas Norvilas, Vilma Valčeckienė, Vaidas Dirsė, Eglė Gineikienė-Valentinė, Artūras Jakubauskas, Laimonas Griškevičius

Blood (2024) 144 (Supplement 1): 7319.

https://doi.org/10.1182/blood-2024-208585

Published: 2024

Journal Articles

Individualized Sequential Allogeneic Stem Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Patients with Active Disease

Andrius Zucenka, Lukas Kevličius, Tautvilė Smalinskaitė, Guoda Daukėlaitė, Linas Davainis, Igoris Trociukas, Artūras Slobinas, Renata Jucaitienė, Inga Šlepikienė, Rita Čekauskienė, Vaida Jaraminė, Justė Strumskytė, Artūras Jakubauskas, Laimonas Griškevičius

Blood (2024) 144 (Supplement 1): 3487.

https://doi.org/10.1182/blood-2024-203229

Published: 2024

Journal Articles

MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

Blood (2024) 144 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2024-199211

Published: 2024

Journal Articles

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Blood (2024) 144 (5): 541–551.

https://doi.org/10.1182/blood.2023023625

Published: 2024

Includes: Supplemental data

Journal Articles

Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 657.

https://doi.org/10.1182/blood-2023-182823

Published: 2023

Journal Articles

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2023-181709

Published: 2023

Journal Articles

Real-World Comparison of Venetoclax-Based Treatment Versus Intensive Chemotherapy As Bridging to Allogeneic Stem Cell Transplantation in MDS-IB2 Patients

Andrius Zucenka, Birutė Davainienė, Vilmantė Vaitekėnaitė, Rūta Čepulytė, Linas Davainis, Guoda Daukėlaitė, Lukas Kevličius, Regina Pileckytė, Igoris Trociukas, Laimonas Griškevičius

Blood (2023) 142 (Supplement 1): 6474.

https://doi.org/10.1182/blood-2023-178611

Published: 2023

Journal Articles

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Blood (2023) 142 (Supplement 1): 323.

https://doi.org/10.1182/blood-2023-184703

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Hypomethylating agents or chemotherapy in combination with venetoclax and gilteritinib for FLT3-mutated Acute Myeloid Leukemia

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group

Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group

Next-generation sequencing-based mutation profile in secondary compared to de novo acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: A study from the ALWP/EBMT

Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication

Conditioning with alkylating agents, cytarabine, cladribine, hypomethylating agents, and venetoclax (ARCHIVE) for upfront allogeneic stem cell transplantation in patients with active Acute Myeloid Leukemia or myelodysplastic syndrome with increased blasts-2

Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party

Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT

No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

Frontline Sequential Allogeneic Stem Cell Transplantation for Newly Diagnosed Acute Myeloid Leukemia with 3q26.2/ Mecom Rearrangement

Individualized Sequential Allogeneic Stem Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Patients with Active Disease

MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Real-World Comparison of Venetoclax-Based Treatment Versus Intensive Chemotherapy As Bridging to Allogeneic Stem Cell Transplantation in MDS-IB2 Patients

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only